We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Courtney
Himsworth
Courtney.Himsworth@gosh.nhs.uk
emily
holt
Emily.Holt@gosh.nhs.uk
Mr
John
Anderson
j.anderson@ucl.ac.uk
Tetiana
Petreman
Tetiana.Petreman@gosh.nhs.uk
Malignant neoplasms of ill-defined, secondary and unspecified sitesMalignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Background: The overall survival of children with solid tumors needs to be improved and new methods for detecting and monitoring paediatric tumors are required. Tumor biopsies help us understand the genetic make-up of cancer but these are intrusive procedures. Understanding these genetic changes in the tumor is important, as they may open up new treatment options. Scientists can now reliable isolate fragments of DNA from cancer cells, which are shed into a patients’ blood, urine, saliva, etc, which are much less invasive to collect. This DNA is referred to as circulating tumor DNA (ctDNA). We can also now measure and sequence ctDNA to identify genetic changes. Earlier studies suggest that the total amount of ctDNA may predict advanced tumor stage and the quantity of ctDNA isolated from different body sites may depend on the type of tumor.
Aims: This project is a feasibility study to look to see if we can collect serial samples such as blood, cerebrospinal fluid, bone marrow, urine, saliva, etc, from patients and isolate ctDNA from these samples. We then want to compare the genetic changes present in a tumor sample taken at diagnosis and/or relapse to the genetic changes found in the ctDNA isolated from the same patient. We also want to look at the differences in ctDNA found over time and if the amount of ctDNA isolated changes with treatment. We want to determine if this could be a method used to detect new genetic tumor mutations for patients, which may then be targeted by drug therapies.
Eligibility: We want to conduct the study at two hospitals, Great Ormond Street Hospital and Royal Marsden Hospital. The study will include all patients with a possible or confirmed diagnosis of a solid tumor or Langerhan Cell Histiocytosis between the ages of 0-24 years who have signed informed consent.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
• Haematological malignancy (leukaemia or lymphoma). • Lack of appropriate consent/assent.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Tetiana
Petreman
Tetiana.Petreman@gosh.nhs.uk
Courtney
Himsworth
Courtney.Himsworth@gosh.nhs.uk
emily
holt
Emily.Holt@gosh.nhs.uk
Mr
John
Anderson
j.anderson@ucl.ac.uk
The study is sponsored by GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST and funded by ROSETREES .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 46370
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
